CDDF Multi-stakeholder workshop

450231

24/09/2018 - 25/09/2018

CDDF Multi-stakeholder workshop :: © ©CDDF Multi-stakeholder workshop

Deze tekst is niet beschikbaar in het Nederlands. Daarom geven we hem weer in een andere taal.

The incidence of cancer will increase within the next 5 years up to 15 million patients per year worldwide with a further increasing tendency. Therefore, there is a requirement for more emphasis on cancer prevention, research and effective anticancer drugs including a rapid licensing and market availability for the patients. In the EU, the centralized procedure (CP) of the European Medicine Agency (EMA) is mandatory for marketing authorization for innovative anticancer drugs. At variance, numerous independent healthcare systems are in operation across the EU, and each Health Technology Assessment (HTA) body follows its own methodologies and scientific value judgements in the assessment of the added value of an innovative anticancer drug. Consequently, drug access for patients differs considerably within the EU. Initiatives to improve the interface between the different stakeholders are currently on the way, but are unlikely sufficient enough to overcome these fundamental problems.

This workshop will aim at giving an overview about developments in European regulatory and health technology assessment of new cancer drugs as well as at facilitating a collaborative discussion between regulatory bodies, HTA organisations, healthcare providers, academics, patients and industry on the challenges of equal access to personalized therapy within and between European countries.

Following the workshop, a two-hour session focusing on HTA and Access to Innovative Oncology Drugs in Europe is organised by the European Cancer Patient Coalition (ECPC) at the European Parliament on Tuesday 25 September 2018 from 14:30 to 16:30 CET. 

KEY TOPICS

•Personalized medicine
•Access to biomarkers
•Standardization
•Hurdles of getting biomarkers to the market
•Health Technology Assessment
•Harmonization of biomarkers development in Europe

Tel : +32 2 775 02 15

 

Praktische info